Hepatitis B virus conserved genomic region (HBV conserved region)

The Hepatitis B virus (HBV) conserved genomic region refers to specific sequences within the viral genome that are present in all major viral RNA transcripts, including the pregenomic RNA (pgRNA) and the mRNAs for the S, C, P, and X proteins (Source: NIH, PubMed). Because HBV utilizes a compact, overlapping genome structure, certain regions are shared across all transcripts, making them ideal targets for sequence-specific therapeutics (Source: Journal of Hepatology). By targeting these conserved regions, drugs such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) can simultaneously silence the expression of all viral proteins and reduce the levels of pgRNA required for viral replication (Source: Hepatology). This "pan-transcript" knockdown approach is particularly effective at reducing Hepatitis B surface antigen (HBsAg) levels, which is a key goal for achieving a functional cure in chronic hepatitis B patients (Source: Lancet Infectious Diseases). Reducing the viral protein burden helps to alleviate the suppression of the host immune system, potentially allowing for the restoration of an effective anti-viral immune response (Source: Nature Reviews Gastroenterology & Hepatology). Clinical candidates targeting this region, such as JNJ-3989 and Bepirovirsen, are currently being evaluated for their ability to provide sustained viral suppression and HBsAg loss (Source: ClinicalTrials.gov).

Other names

HBV pan-genomic conserved sequenceHBV common transcript regionHBV X/S overlapping regionHBV RNAHBV 3' overlapping region

RNA interference (RNAi) or antisense oligonucleotide (ASO) mediated degradation of viral mRNA transcripts, leading to the knockdown of all viral proteins and pregenomic RNA.